SpeeDx, Sydney, Australia
Resistance Plus InSignia
RAPID POC ID/AST
Diagnostic for Chlamydia trachomatis and Neisseria gonorrhoeae
SpeeDx has developed a rapid, molecular test using polymerase chain reaction (PCR) technology called InSignia™, to assist in detecting chlamydia and active infection of gonorrhoea; additionally, through susceptibility testing, the technology will identify the best antibiotic choice for treatment of gonorrhea. SpeeDx’s technology would be combined with a battery-powered, simple-to-use device developed by another company, QuantuMDx, that could be used in remote or low-resource settings around the world as a point-of-care diagnostic. The SpeeDx technology would be ported onto the QuantuMDx Q-POC™ and the goal is to develop an affordable test to detect Chlamydia trachomatis and Neisseria gonorrhoeae in under an hour, and to determine the susceptibility of the gonorrhea bacteria to three orally administered antibiotics that are generally readily available in low-and middle-income countries (LMICs): cefixime, ciprofloxacin, and azithromycin.
Current Development Stage: Feasibility
CARB-X Investment: Initial investment of up to $1.8m with potential option payments up to $1.9m.
Initial CARB-X Investment Date: April 1, 2021